Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company") (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men's and women's health and respiratory diseases, today announced the signing of an exclusive license and distribution agreement with J&H Co. LTD ("J&H") for the commercialization of Zestra® in South Korea. The exclusive 10-year agreement includes a minimum of $2 million per year in sales to the Company for a total of $20 million over the life of the agreement. "We are pleased to partner with such a successful consumer products distributor such as J&H, making Zestra® available to consumers in South Korea," said Innovus CEO, Dr. Bassam Damaj. "This partnership, our 15 th partnership outside the United States, shows our commitment to making our products commercially available in markets outside of the United States and achieving our 2017 goals of $15 million in revenue and profitability." Zestra® is currently exclusively partnered with Orimed Pharma in Canada, DanaLife in select European markets, Sothema Labs for the Middle East and North Africa, Elis Pharma in Turkey and certain select markets, Oz Biogenics for Myanmar and Vietnam, Biotask in Malaysia and non-exclusively to PT in Hong Kong and certain select Asian markets. Zestra® is approved in Canada, India, Hong Kong, the United Arab Emirates ("UAE"), United Kingdom and Morocco. In addition to the United States, the largest market for Zestra®, Innovus Pharma currently generates Zestra® revenues from the following markets: Canada, Morocco, certain European countries and Hong Kong. About Zestra® and FSI/AD Zestra® is a patented blend of natural oils clinically-proven in double-blind placebo-controlled clinical trials in 276 women to increase in a statistical significant manner the arousal, desire and sexual satisfaction in FSI/AD women. To the Company's knowledge, Zestra® is the first NHP product to receive approval for the indication of FSI/AD in Canada. To date, no product has been approved to treat FSI/AD, a persistent or recurring inability to attain or maintain adequate sexual excitement until the completion of a sexual activity. The diagnosis can also refer to an inadequate lubrication-swelling response normally present during arousal and sexual activity causing personal distress.